Clinical Trials Logo

Recurrent Genital Herpes clinical trials

View clinical trials related to Recurrent Genital Herpes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04979975 Not yet recruiting - Clinical trials for Recurrent Genital Herpes

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Start date: December 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To evaluate the pharmacokinetics of repeat-dose UB-621 in RGH patients

NCT ID: NCT04714060 Not yet recruiting - Clinical trials for Recurrent Genital Herpes

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

Start date: October 1, 2023
Phase: Phase 2
Study type: Interventional

A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection

NCT ID: NCT00171990 Completed - Clinical trials for Recurrent Genital Herpes

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Start date: January 2003
Phase: Phase 3
Study type: Interventional

This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.